

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the specification:

Listing of Claims

Claim 1. (original) A rapidly disintegrating tablet comprising:

- at least one active substance
- silicified microcrystalline cellulose, and
- optional excipients.

Claim 2. (original) The rapidly disintegrating tablet according to claim 1, wherein the active substance is selected from the group of antibiotics.

Claim 3. (previously presented) The rapidly disintegrating tablet according to ~~claims 1 or 2~~ claim 1, wherein the active substance is amoxicillin in combination with clavulanic acid.

Claim 4. (original) The rapidly disintegrating tablet according to claim 3, wherein the amoxicillin is in the form of amoxicillin 20 trihydrate.

Claim 5. (original) The rapidly disintegrating tablet according to claim 3, wherein the clavulanic acid is in the form of potassium clavulanate.

Claim 6. (previously presented) The rapidly disintegrating tablet according to ~~any of claims 3 to 5~~ claim 3, wherein the ratio of amoxicillin to clavulanic acid is in the range of 2 :1 to 30 :1.

Claim 7. (previously presented) The rapidly disintegrating tablet according to ~~any of claims 3 to 5~~ claim 3, wherein the ratio of amoxicillin to clavulanic acid is 4 :1.

Claim 8. (previously presented) The rapidly disintegrating tablet according to ~~any of claims 3 to 5~~ claim 3, wherein the ratio of amoxicillin to clavulanic acid is 7 :1.

Claim 9. (original) The rapidly disintegrating tablet according to claim 1, wherein the proportion of the active substance in the tablet is 5 to 70 % by weight of the tablet.

Claim 10. (original) The rapidly disintegrating tablet according to claim 1, wherein the ratio of the active substance and silicified microcrystalline cellulose is 0.5 : 1 to 2.5 : 1.

Claim 11. (original) The rapidly disintegrating tablet according to claim 1 wherein the proportion of silicified microcrystalline cellulose is 30 to 95% by weight.

Claim 12. (original) The rapidly disintegrating tablet according to claim 1, wherein hydrogenated castor oil is contained as a lubricant.

Claim 13. (canceled) Use of the rapidly disintegrating tablet according to any of the preceding claims as an orodispersible tablet or as a dispersible tablet.

Claim 14. (canceled) Use of the rapidly disintegrating tablet according to any of claims 1 to 12 in the manufacture of a medicament for the treatment of pediatric patients.

Claim 15. (original) An orodispersible tablet comprising amoxicillin, clavulanic acid and silicified microcrystalline cellulose.

Claim 16. (original) A dispersible tablet comprising amoxicillin, clavulanic acid and silicified microcrystalline cellulose.

Claim 17. (original) A process for the manufacture of a rapidly disintegrating tablet according to claim 1 comprising the steps of:

- blending the at least one active substance, silicified microcrystalline cellulose and optional excipients;
- homogenizing the obtained mixture;
- sieving the homogenized mixture; and
- forming tablets therefrom.